What Urologists Want to Know:
Addressing Current Questions and Controversies in the Management of Early and Advanced Prostate Cancer

TARGET AUDIENCE
This activity has been designed to meet the educational needs of urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

OVERVIEW OF ACTIVITY
Prostate cancer is the most frequently diagnosed cancer and the third leading cause of cancer death in men. As data have accumulated documenting the efficacy of a number of therapies before the standard introduction of chemotherapy, the needs of the practicing urologist have grown exponentially. Given that patients with prostate cancer could potentially receive multiple lines of therapy before chemotherapy, the urologist and his/her team in many instances may elect to or be called upon to extend their care of patients in the advanced disease setting. Additionally, urologists are often the first physicians to initiate discussions about and/or recommend treatment with cytotoxic therapy. As such, it seems quite clear that additional resources are necessary to assist these clinicians as they contend with the complexity of decision-making throughout the course of prostate cancer treatment.

These video proceedings from a live CME symposium use the perspectives of leading genitourinary cancer experts to explore significant advances in the field of prostate cancer research. This CME activity will help urologists and other allied healthcare professionals with the formulation of up-to-date clinical management strategies for prostate cancer.

LEARNING OBJECTIVES
- Review existing and emerging research data evaluating the use of novel biomarkers and gene signatures to refine the risk of recurrence for patients with localized prostate cancer, and use the results from available molecular assays to guide clinical decision-making.
- Evaluate emerging clinical trial evidence with the use of available and investigational secondary hormonal agents in the management of nonmetastatic prostate cancer, and consider this information in the discussion of protocol and nonresearch treatment options.
- Explore published research information on the use of cytotoxic therapy in the setting of hormone-sensitive advanced prostate cancer, and refer appropriate candidates for consultation with a medical oncologist to discuss the risks and benefits of this approach.
- Compare and contrast the efficacy and safety of denosumab and bisphosphonates in the treatment and/or prevention of prostate cancer skeletal metastases.
- Consider available research data and expert perspectives on the efficacy and safety of radium-223 chloride as monotherapy or in combination with other treatment modalities, and use this information to appropriately integrate this novel radiopharmaceutical agent into current nonresearch treatment algorithms.
- Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic prostate cancer.
- Counsel appropriately selected patients with prostate cancer about the availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUAProstate17/CME.
CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Raoul S Concepcion, MD**
Director
The Comprehensive Prostate Center
Nashville, Tennessee

**Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Integra Connect; **Speakers Bureau:** Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Sanofi Genzyme.

**Leonard G Gomella, MD**
The Bernard W Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director
Jefferson Sidney Kimmel Cancer Center
Clinical Director, Jefferson Sidney Kimmel Cancer Center Network
Editor-in-Chief, *Canadian Journal of Urology*
Philadelphia, Pennsylvania

**Advisory Committee:** Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc.

**Daniel W Lin, MD**
Professor and Chief of Urologic Oncology
Department of Urology
Bridges Endowed Professorship in Prostate Cancer Research
University of Washington
Seattle, Washington

**Consulting Agreement:** Astellas Pharma Global Development Inc; **Contracted Research:** GenomeDx, Genomic Health Inc, MDxHealth.

David I Quinn, MBBS, PhD
Medical Director
Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

**Advisory Committee and Consulting Agreements:** Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Exelixis Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme.

**A Oliver Sartor, MD**
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

**Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, OncoGenex Pharmaceuticals Inc, Sanofi Genzyme, Tokai Pharmaceuticals Inc; **Contracted Research:** Bayer HealthCare Pharmaceuticals, Endocyte Inc, Innocrin, Johnson & Johnson Pharmaceuticals, Sanofi Genzyme.


**RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS** — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, a Pfizer Company, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Genomic Health Inc and Sanofi Genzyme.

**Hardware/Software Requirements:**
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

**Last review date:** August 2017  
**Expiration date:** August 2018
Raoul S Concepcion, MD


Daniel W Lin, MD


David I Quinn, MBBS


Silberstein J et al. Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (Abi) or enzalutamide (Enza). Proc ASCO 2017; Abstract 132.

Oliver Sartor, MD


Leonard G Gomella, MD


Ryan CJ et al. Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician’s choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Proc ASCO 2016;Abstract TPS5087.

A multicenter phase 2, randomized, double-blind, efficacy and safety study of enzalutamide versus bicalutamide in men with prostate cancer who have failed primary androgen deprivation therapy. NCT01664923